Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesTransplantAetna Liver Transplantation Coverage Update | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0596

    Liver Transplantation

    Customize your policy alerts

    Sign up for Aetna Policy 0596 alerts

    Get alerted when Policy 0596 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, covered indications, contraindications, experimental/investigational exclusions, CPT/HCPCS/ICD-10 codes related to liver transplantation, and background evidence. This part (1 of 5) includes policy criteria for candidate selection, covered diagnoses, retransplantation, contraindications, investigational items, and code lists.

    Policy Summary
    PayerAetna
    PolicyLiver Transplantation
    Policy CodePolicy 0596
    Change TypeNo material change
    Effective DateMar 5, 2002
    Last ReviewAug 9, 2023
    Next Review DateJun 27, 2024
    Key ActionProviders must document MELD/PELD scores, UNOS Regional Review Board approval when applicable, and that the member meets the transplanting institution's selection criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this update.

    NumerousCovered Indications (examples)
    20+Experimental/Investigational items
    2002-03-05Effective Date
    lowOverall evidence certainty
    2024-06-27Next review

    Coverage Summary

    This policy part is covered with criteria for orthotopic liver transplantation (OLT) and related procedures: it defines candidate selection (age-based rules using MELD/PELD thresholds, UNOS Regional Review Board or institutional selection criteria), lists covered diagnoses and examples of medically necessary indications (cholestatic, hepatocellular, vascular, metabolic, malignancy indications, fulminant hepatic failure, trauma, hepato-pulmonary syndrome), permits retransplantation when the initial transplant was for a covered indication, enumerates absolute contraindications, and identifies interventions considered experimental/investigational (e.g., bioartificial liver, MARS, machine perfusion modalities, xenotransplantation, everolimus). The part also contains the CPT/HCPCS/ICD-10 code lists that are covered when selection criteria are met and notes CPT/HCPCS items not covered. Criteria require documentation of MELD or PELD scores, UNOS or institutional approvals when applicable, and exclusion for absolute contraindications.

    Key thresholds & policy dates
    MELD rule> 10 required for adolescents >=12 and adults to meet primary eligibility (otherwise UNOS RRB approval or institutional criteria required)
    Hepato-pulmonary syndrome - PaO2PaO2 < 60 mm Hg (plus other HPS criteria required)
    Hepato-pulmonary syndrome - AaO2 gradientAaO2 gradient > 20 mm Hg (in supine or standing position)
    Policy Summary
    PayerAetna
    PolicyLiver Transplantation
    Policy CodePolicy 0596
    Change TypeNo material change
    Effective DateMar 5, 2002
    Last ReviewAug 9, 2023
    Next Review DateJun 27, 2024
    Key ActionProviders must document MELD/PELD scores, UNOS Regional Review Board approval when applicable, and that the member meets the transplanting institution's selection criteria.
    SourceLink
    On This Page
    Coverage SummaryMedical-Necessity CriteriaCodingProvider Actions & RequirementsBackground & Evidence SummaryDefinitions & ThresholdsRevision History
    Porto-pulmonary hypertension - mPAPMean pulmonary artery pressure by catheterization < 35 mm Hg
    PLR cut-offPlatelet-to-lymphocyte ratio commonly reported cut-off = 150
    Transient elastography (examples)Study-reported TE cut-offs varied (e.g., >7.9 kPa, >8.5 kPa to indicate graft damage; reported range ~7.3–12.3 kPa)
    OrganOx Metra donor limitsDBD or DCD donors ≤ 40 y; functional warm ischemic time ≤ 20 min; macro-steatosis ≤ 15%; intended preservation up to 12 h (device supports up to 24 h)
    Policy datesEffective: 2002-03-05; Last review: 2023-08-09; Next review: 2024-06-27

    Medical-Necessity Criteria

    Medical Necessity - Candidate Eligibility

    Covered when ALL of the following are met:

    Medical Necessity - Candidate Eligibility (top)

    • Age group and approvals

      • Adolescents (>=12) and adults: Adolescents 12 years of age or older and adults: one of: MELD score greater than 10; OR approved for transplant by the UNOS Regional Review Board; OR meet the transplant institution's selection criteria>10 (MELD)

        MELD/PELD definitions and guidance in Appendix

      • Children <12: Children less than 12 years of age who meet the transplanting institution's selection criteriaPELD per institution
    • Additional review for some cases: In absence of an institution's selection criteria, requests for liver transplantation are subject to medical necessity review for children, and for adolescents and adults with a MELD score of 10 or less who have not been approved by the UNOS Regional Review BoardMELD <= 10

      Document MELD/PELD and UNOS/institutional approvals

    Document requirements: Providers must document MELD or PELD scores, UNOS Regional Review Board approval when applicable, and that member meets transplanting institution's selection criteria

    From provider actions

    Medically Necessary Indications (examples / not all-inclusive)

    Orthotopic liver transplantation is medically necessary for ESLD due to any of the following when medical necessity criteria in Section I.A. are met:

    • Cholestatic diseases

      • Biliary atresia
      • Familial cholestatic syndromes
      • Primary biliary cirrhosis
      • PSC with secondary biliary cirrhosis: Primary sclerosing cholangitis with development of secondary biliary cirrhosis
    • Hepatocellular diseases

    Retransplantation

    Retransplantation is medically necessary if the initial transplant was performed for a covered indicationinitial transplant for covered indication

    Absolute Contraindications (Not Medically Necessary)

    Liver transplantation is considered not medically necessary for members with any of the following absolute contraindications:

    • Active sepsis outside biliary tract: Active sepsis outside the biliary tract
    • Other effective treatments available: Other effective medical treatments or surgical options are available
    • Significant organ system failure: Presence of significant organ system failure other than kidney, liver or small bowel
    • Extra-hepatic malignancy
    • Severe cardiopulmonary disease

    Experimental and Investigational (Not Covered)

    The following interventions are considered experimental and investigational due to unestablished safety/effectiveness and are not covered:

    • Basiliximab for induction immunosuppression in individuals undergoing liver transplantation

      Listed as investigational in policy

    • Bioartificial liver transplantation
    • Biomarkers for acute rejection: Biomarkers for diagnosis of acute allograft rejection including: acid labile nitroso-compounds (NOx), serum amyloid A protein, procalcitonin, peripheral blood T-cell activation, interleukin 2 (IL-2) receptor, guanylate-binding protein-2 mRNA, graft-derived cell-free DNA, pi-glutathione S-transferase, alpha-glutathione S-transferase and serum HLA class I soluble antigens
    • Ectopic or auxiliary liver transplantation

    Coding

    CPT codes covered if selection criteria are metCPTCovered
    47133Donor hepatectomy (including cold preservation), from cadaver donor.
    47135Liver allotransplantation; orthotopic; partial or whole, from cadaver or living donor, any age.
    47140Donor hepatectomy (including cold preservation), from living donor; left lateral segment only (segments II and III).
    47141Total left lobectomy (segments II, III and IV).
    47142Total right lobectomy (segments V, VI, VII and VIII).
    47143Backbench standard preparation of cadaver donor whole liver graft prior to allotransplantation; without trisegment or lobe split.
    47144With trisegment split of whole liver graft into two partial liver grafts.
    47145With lobe split of whole liver graft into two partial liver grafts.
    47146Backbench reconstruction of cadaver or living donor liver graft prior to allotransplantation; venous anastomosis, each.
    47147Arterial anastomosis, each.
    1–10 of 18
    1/2
    CPT/HCPCS codes not covered (procedures/interventions listed as experimental/investigational)mixedNot Covered
    no_specific_codeMolecular Adsorbent Recirculating System (MARS) - no specific code
    no_specific_codeNormothermic machine perfusion of donor liver - no specific code
    no_specific_codeHypothermic machine perfusion - no specific code
    no_specific_codeScaffold-based transplantation - no specific code
    no_specific_codeOrganOx metra System - no specific code
    HCPCS codes not coveredHCPCSNot Covered
    B4155Enteral formula, nutritionally incomplete/modular nutrients, administered through an enteral feeding tube, 100 calories = 1 unit.
    J0480Injection, basiliximab, 20 mg.
    J2598Injection, vasopressin, 1 unit.
    J2599Injection, vasopressin (american regent) not therapeutically equivalent to j2598, 1 unit.
    ICD-10 codes covered if selection criteria are metICD-10Covered
    B16.0
    B16.2
    B18.0
    B18.1
    B19.11Acute hepatitis B with hepatic coma.
    B16.1
    B16.9
    B19.10Acute hepatitis B without mention of hepatic coma.
    B17.10Acute hepatitis C without hepatic coma.
    B17.11Acute hepatitis C with hepatic coma.
    1–10 of 50
    1/5
    ICD-10 codes not covered for indications listedICD-10Not Covered
    A41.9Sepsis, unspecified organism.
    C24.0Malignant neoplasm of extrahepatic bile duct.
    Z76.82Awaiting organ transplant status [liver].
    Z94.4Liver transplantation status [not covered for the use of everolimus to prevent organ rejection].

    Provider Actions & Requirements

    Prior Authorization

    Medical necessity review when institutional criteria absent or MELD <=10

    Medical necessity review required when institutional selection criteria are not provided, or for adolescents and adults with a MELD score of 10 or less who have not been approved by the UNOS Regional Review Board.

    Documentation Required

    Document MELD/PELD, UNOS approval, and institution selection criteria

    Document MELD/PELD scores, UNOS Regional Review Board approval (when applicable), and that the member meets the transplanting institution's selection criteria.

    Denial Risk

    Denial risk for absolute contraindications

    Claims may be denied if any absolute contraindication to liver transplantation is present.

    • Active sepsis outside the biliary tract
    • Presence of significant organ system failure other than kidney, liver or small bowel
    • Other absolute contraindications listed in the Contraindications section
    Documentation Required

    Use background evidence to inform clinical decision-making

    Use the background evidence in this policy to inform clinical decision-making and candidate selection. Document how applicable evidence influenced the evaluation and treatment plan.

    Documentation Required

    Be aware of evidence limitations when applying policy

    Be aware of the limitations of the evidence cited in this policy when making coverage determinations; document any instances where evidence limitations affected the clinical recommendation or decision.

    Documentation Required

    Document preservation technique and ischemia times (machine perfusion evidence)

    Consider available evidence regarding machine perfusion technologies when evaluating donor liver preservation strategies. Document the preservation technique used and relevant ischemia times in the medical record.

    Documentation Required

    Document EBV viral load monitoring rationale

    EBV viral load monitoring may be considered where clinically appropriate; document the rationale for testing and how results influenced management.

    Documentation Required

    Reference policy dates and revision history in submissions

    When submitting coverage determinations or prior authorization requests, reference this policy number (0596), the effective date (2002-03-05), and any applicable revision history or policy dates.

    Background & Evidence Summary

    Background rationale: liver transplantation is an effective therapy for fulminant hepatic failure and many chronic and metabolic liver diseases; MELD (adults) and PELD (children) scoring systems are used to prioritize candidates and identify urgency, with MELD scores <10 rarely requiring transplant and UNOS Regional Review Boards available to approve exceptions. Pediatric considerations include frequent use of reduced-size, split, and living-donor left-lobe grafts to address donor scarcity and size mismatch. Emerging and assessed technologies/interventions summarized include bioartificial liver systems and albumin-dialysis (MARS) with mixed survival impacts but improvements in bilirubin and encephalopathy; normothermic machine perfusion (NMP-L), hypothermic/sub-normothermic machine perfusion (HMP/SNMP) and hypothermic oxygenated perfusion (HOPE) with potential for better preservation and reduced biliary complications versus static cold storage but requiring more RCT data; OrganOx Metra and NRP strategies for extended preservation; peri-operative therapies evaluated include sorafenib (no clear survival benefit), ursodeoxycholic acid (no prevention of acute cellular rejection), peri-operative immuno-nutrition (some reduction in infections and shorter stays), vasopressin/terlipressin (limited renal benefit evidence), and immunosuppression agents including basiliximab and everolimus (basiliximab evidence limited/low-certainty; everolimus not recommended by NICE for prevention of rejection). Xenotransplantation, scaffold-based transplantation, hepatocyte transplantation and several perfusion/transport devices are considered investigational.

    Evidence ItemKey Finding
    MARS randomized trials/meta-analysesMeta-analyses and RCTs show MARS reduces bilirubin and improves hepatic encephalopathy but overall no consistent mortality benefit; some meta-analyses show no significant mortality reduction (RR 0.56; 95% CI 0.28–1.14) while others show benefit in acute liver failure (RR 0.61; 95% CI 0.38–0.97)
    HepatAssist bioartificial liver RCT (HepatAssist)HepatAssist RCT (n=171) showed no overall significant survival benefit; marginal survival benefit for fulminant/subfulminant hepatic failure (risk ratio = 0.56; p=0.048)
    NMP-L early clinical studiesEarly clinical NMP-L trials demonstrated feasibility and safety with potential improved function vs static cold storage; RCT data pending and larger randomized studies needed
    Hypothermic machine perfusion (HMP) / HOPE RCT resultsRandomized trial of hypothermic oxygenated perfusion (HOPE) vs SCS in DCD livers showed reduced non-anastomotic biliary strictures (6% vs 18%; RR 0.36) and lower early allograft dysfunction (26% vs 40%; RR 0.61)
    Machine perfusion (HMP/SNMP) pre-clinical mitochondrial protectionAnimal data and network analyses indicate HMP and SNMP provide superior preservation of graft ATP and mitochondrial protection compared with other methods
    NLR pre-transplant meta-analysisElevated pre-transplant neutrophil-to-lymphocyte ratio associated with worse OS (HR 2.22), recurrence-free survival (HR 3.77), and disease-free survival (HR 2.51) after LT for HCC
    PLR pre-transplant meta-analysisHigh pre-transplant platelet-to-lymphocyte ratio (commonly cut-off ~150) associated with increased post-transplant HCC recurrence (OR 3.33)
    Transient elastography (TE) performance post-LTTE performed best for detecting recurrent fibrosis post-LT (summary OR 21.17); reported cut-offs varied widely (7.3–12.3 kPa); small studies suggest cut-offs >7.9–8.5 kPa may indicate graft damage
    IL-2 receptor and other biomarkers for acute rejectionSystematic review identified multiple biomarkers; IL-2 receptor had highest reported sensitivity (89%) and specificity (81%), but none replace biopsy
    Basiliximab induction evidenceNetwork meta-analysis of RCTs (25 trials, 3,271 subjects) found low-certainty evidence basiliximab may lower all-cause mortality (HR 0.53) and graft failure (HR 0.44) versus glucocorticoid induction, but evidence is uncertain and trials at risk of bias
    OrganOx Metra device summaryOrganOx metra is a transportable normothermic perfusion device supporting donor livers (DBD or DCD ≤40 y, functional warm ischemia ≤20 min, macro-steatosis ≤15%) and intended to sustain livers for total preservation times up to ~12 hours (device supports up to 24 h)

    Definitions & Thresholds

    Definitions:

    MELD — Model for End-Stage Liver Disease; numerical scale (6–40) predicting 3-month mortality using bilirubin, prothrombin time and creatinine.

    PELD — Pediatric End-stage Liver Disease scoring system for candidates under age 12, incorporating bilirubin, prothrombin time, albumin, growth failure, and age <1 year.

    MARS — Molecular Adsorbent Recirculating System; an extracorporeal albumin dialysis device for liver support.

    NMP-L — Normothermic Machine Perfusion of the Liver; organ preservation technique at physiologic temperature enabling viability assessment.

    TE — Transient Elastography; noninvasive measurement of liver stiffness (reported in kPa).

    NLR — Neutrophil-to-Lymphocyte Ratio; a pre-operative prognostic marker.

    PLR — Platelet-to-Lymphocyte Ratio; a pre-operative prognostic marker (cut-off commonly reported as 150).

    HMP — Hypothermic Machine Perfusion.

    SNMP — Sub-normothermic Machine Perfusion.

    NMP — Normothermic Machine Perfusion.

    OLT — Orthotopic Liver Transplantation.

    PE — Pulmonary Embolism.

    PVT — Portal Vein Thrombosis.

    DBD — Donor after Brain Death.

    DCD — Donor after Circulatory Death.

    SCS — Static Cold Storage.

    HOPE — Hypothermic Oxygenated Perfusion.

    NRP — Normothermic Regional Perfusion.

    NAS — Non-anastomotic Biliary Strictures.

    PTLD — Post-Transplant Lymphoproliferative Disease.

    Thresholds (detailed)
    MELD score> 10 for adolescents >=12 and adults to meet primary criterion (otherwise require UNOS Regional Review Board approval or institutional selection criteria)
    PaO2 (Hepato-pulmonary syndrome)PaO2 < 60 mm Hg (with other HPS selection criteria)
    AaO2 gradient (Hepato-pulmonary syndrome)AaO2 gradient > 20 mm Hg in supine or standing position
    Porto-pulmonary hypertensionMean pulmonary artery pressure by catheterization < 35 mm Hg
    Transient elastography (TE) cut-offsStudy-reported TE thresholds varied; examples: >7.9 kPa or >8.5 kPa to indicate graft damage; overall reported range ~7.3–12.3 kPa
    TE for ACR exclusionTE <4.2–5.3 kPa reported to help exclude acute cellular rejection in some studies
    PLR cut-offPre-operative PLR commonly reported cut-off = 150 (associated with higher HCC recurrence post-LT)

    Revision History

    2002-03-05effective_date

    Policy effective date: 2002-03-05.

    2023-08-09last_review

    Policy last reviewed on 2023-08-09.

    2024-06-27next_reviewLatest

    Next scheduled policy review on 2024-06-27.

    Alcoholic cirrhosis
  1. Chronic active hepatitis with cirrhosis (hepatitis B or C)
  2. Cryptogenic cirrhosis
  3. Idiopathic autoimmune hepatitis
  4. Post-necrotic cirrhosis due to hepatitis B surface antigen negative state
  5. Malignancies

    • Primary HCC confined to liver: Primary hepatocellular carcinoma confined to the liver when ALL of the following are met: any lung metastases responsive to chemotherapy; member is not a candidate for subtotal liver resection; member meets UNOS criteria for tumor size and number; no identifiable extra-hepatic spread to lymph nodes, abdominal organs, bone or other sites; and no macrovascular involvementUNOS tumor size/number criteria

      Consistent with UNOS guidelines

    • Hepatoblastoma (<12): Hepatoblastomas in members <12 years when ALL of the following are met: member is not a candidate for subtotal liver resection; member meets UNOS criteria for tumor size and number; there is no identifiable extra-hepatic spread to lungs, abdominal organs, bone or other sites (note: spread to veins and lymph nodes does not disqualify)UNOS criteria

      Pediatric note on venous/lymph node spread

    • Epithelioid hemangioendotheliomas
    • Intra-hepatic cholangiocarcinomas confined to liver: Intra-hepatic cholangiocarcinomas confined to the liver
    • Large unresectable fibrolamellar HCCs: Large, unresectable fibrolamellar HCCs
    • Metastatic neuroendocrine tumors with severe symptoms and metastases restricted to the liver, unresponsive to adjuvant therapy after aggressive surgical resection including excision of the primary lesion and reduction of hepatic metastases
  6. Vascular diseases

    • Budd-Chiari syndrome
    • Veno-occlusive disease
  7. Metabolic disorders

    • Alpha-1-antitrypsin deficiency: Alpha 1-antitrypsin deficiency
    • Hemochromatosis
    • Inborn errors of metabolism
    • Protoporphyria
    • Wilson's disease
  8. Miscellaneous

    • Familial amyloid polyneuropathy
    • Polycystic disease of the liver
    • Porto-pulmonary hypertension with mean pulmonary artery pressure by catheterization < 35 mm Hgmean PAP < 35 mm Hg
  9. Toxic and trauma

    • Fulminant hepatic failure (toxic): Toxic reactions: Fulminant hepatic failure (e.g., mushroom poisoning, acetaminophen overdose)
    • Trauma
  10. Hepato-pulmonary syndrome when ALL of the following selection criteria are met: arterial hypoxemia (PaO2 < 60 mm Hg or AaO2 gradient > 20 mm Hg in supine or standing position); chronic liver disease with non-cirrhotic portal hypertension; and intrapulmonary vascular dilatation indicated by contrast-enhanced echocardiography, technetium-99 macroaggregated albumin perfusion scan, or pulmonary angiographyPaO2 < 60 mm Hg; AaO2 > 20 mm Hg
  11. Systemic sepsis
  12. Inability to comply with pharmacotherapy: Inability to comply with regular pharmacotherapy
  13. Everolimus to prevent rejection: Everolimus to prevent organ rejection after liver transplantation

    NICE guidance not recommended

  14. Factor V Leiden and F2 testing for member scheduled to receive partial liver transplant for primary sclerosing cholangitis
  15. Hepatocyte transplantation: Hepatocellular (hepatocyte) transplantation
  16. Hypothermic machine perfusion for reduction of early allograft dysfunction and biliary complications after LT

    Listed investigational in policy despite emerging evidence

  17. Liver transplantation for other malignancies: Liver transplantation for malignancies other than those listed as covered above
  18. LT for extra-hepatic hilar cholangiocarcinoma: Liver transplantation for the treatment of extra-hepatic hilar cholangiocarcinoma
  19. NGAL measurements: Measurements of plasma and urinary NGAL for predicting acute kidney injury following orthotopic liver transplantation
  20. MARS for PFIC: Molecular Adsorbent Recirculating System (MARS) for treatment of progressive familial intrahepatic cholestasis
  21. Normothermic machine perfusion of donor liver
  22. OrganOx metra system: OrganOx metra System for transportation and preservation of the liver prior to transplantation

    Device-specific criteria listed in background

  23. Peri-operative vasopressin: Peri-operative use of vasopressin in liver transplantation
  24. Peri-operative sorafenib: Peri-operative use of sorafenib in liver transplantation
  25. Scaffold-based transplantation (combination of xeno-organ and cell transplantations)
  26. Transient elastography for ACR: Transient elastography for diagnosis of acute cellular rejection following liver transplantation
  27. Ursodeoxycholic acid to prevent ACR: Ursodeoxycholic acid (UDCA) as adjuvant to prevent acute cellular rejection after liver transplantation
  28. Xenotransplantation
  29. OrganOx Metra donor criteriaSuitable for DBD or DCD ≤40 y; functional warm ischemic time ≤20 min; macro-steatosis ≤15%; sustains donor livers for intended total preservation up to 12 h (device supports up to 24 h)